Skip to main content

Advertisement

SpringerLink
Log in

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Phoenix KN, Vumbaca F, Claffey KP (2008) Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat Feb 7 [Epub ahead of print]

  2. Goodwin PJ, Pritchard KI, Fantus IG, Ennis M, Clemons M, Graham M (2006) Metformin lowers fasting insulin levels in hyperinsulinemic early stage breast cancer patients—results of a Phase II study. Breast Cancer Res Treat 100(suppl):A2085

    Google Scholar 

  3. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51

    Article  PubMed  CAS  Google Scholar 

  4. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S (2006) Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119(1):236–238

    Article  PubMed  CAS  Google Scholar 

  5. Pollak MN, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KI (2006) Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J Clin Oncol 24(18S):524

    Google Scholar 

  6. Mulligan AM, O’Malley FP, Ennis M, Fantus IG, Goodwin PJ (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106(1):39–47

    Article  PubMed  CAS  Google Scholar 

  7. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108(8):1167–1174

    PubMed  CAS  Google Scholar 

  8. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (New York, NY) 310(5754):1642–1646

    CAS  Google Scholar 

  9. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269–10273

    Article  PubMed  CAS  Google Scholar 

  10. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes care 29(2):254–258

    Article  PubMed  Google Scholar 

  11. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ Clin Res Ed 330(7503):1304–1305

    Article  Google Scholar 

  12. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, Chauveau P, Dulbecco P, Guerin C, Haegy JM et al (1995) Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 18(6):779–784

    Article  PubMed  CAS  Google Scholar 

  13. Hamada K, Sasaki T, Koni PA, Natsui M, Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, Miyazaki J, Suda T, Itoh H, Nakao K, Mak TW, Nakano T, Suzuki A (2005) The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19(17):2054–2065

    Article  PubMed  CAS  Google Scholar 

  14. Blancher C, Moore JW, Robertson N, Harris AL (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3’-kinase/Akt signaling pathway. Cancer Res 61(19):7349–7355

    PubMed  CAS  Google Scholar 

  15. Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK, Durden DL (2001) PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98(8):4622–4627

    Article  PubMed  CAS  Google Scholar 

  16. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40(8–9):685–693

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Signaling Biology, Ontario Cancer Institute, University Health Network, Toronto, Canada

    Vuk Stambolic

  2. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada

    James R. Woodgett, I. George Fantus & Pamela J. Goodwin

  3. University Health Network, Toronto, Canada

    I. George Fantus

  4. Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Canada

    Kathleen I. Pritchard

Authors
  1. Vuk Stambolic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James R. Woodgett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. George Fantus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathleen I. Pritchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pamela J. Goodwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vuk Stambolic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stambolic, V., Woodgett, J.R., Fantus, I.G. et al. Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. Breast Cancer Res Treat 114, 387–389 (2009). https://doi.org/10.1007/s10549-008-0015-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-008-0015-4

Keywords

Search

Navigation